Associate Professor, Department of Medicine (Hematology/Oncology), UCSF; Leader, Prostate Cancer Program, UCSF Helen Diller Family Comprehensive Cancer Center
Education
Dartmouth College, Hanover, NH, BA, 1984-1988, Biology
University of California, San Francisco, CA, 1990-1991, Pathology
University of California, San Francisco, CA, MD, 1988-1993, Medical School
Brigham and Womens Hospital, Boston, MA, Residency, 1993-1996, Internal Medicine
Dana Farber Cancer Institute, Boston, MA, Fellowship, 1996-1999, Oncology
Professional Experience
-
1993-2004
Clinical Instructor in Medicine, Harvard Medical School, Boston, MA
-
1996-2004
Associate Physician, Brigham and Women's Hospital, Boston, MA
-
1999-2004
Instructor in Medicine, Dana Farber Cancer Institute, Boston, MA
-
1999-2004
Post-doctoral Fellow, Dana Farber Cancer Institute, Boston, MA
-
1999-2004
Visiting Scholar, Whitehead Institute Center for Genomic Research, MIT, Cambridge, MA
-
2004-2008
Assistant Professor, Department of Medicine, Duke University Medical Center, Durham, NC
-
2004-2008
Assistant Professor, Department of Molecular Genetics and Microbiology, Duke University, Durham, NC
-
2005-2010
Associate Member, Duke Comprehensive Cancer Center, Durham, NC
-
2008-2010
Associate Professor, Department of Medicine, Duke University Medical Center, Durham, NC
-
2008-2010
Associate Professor, Department of Molecular Genetics and Microbiology, Duke University, Durham, NC
-
2010-present
Associate Professor in Residence, Department of Medicine, University of California San Francisco, San Francisco, CA
Honors & Awards
- 1997
National Cancer Institute Oncology Fellowship, Dana Farber Cancer Institute, Boston MA - 1998
Friends of Dana Farber Oncology Fellowship, Dana Farber Cancer Institute, Boston MA - 1998
AACR meeting Travel Award, New research approaches in the Prevention and Cure of Prostate Cancer - 1999
American Society of Clinical Oncology, Young Investigator Award - 2000
Hershey Family Foundation, Young Investigator Award, Beth-Israel Deaconess Hospital - 2001
CapCURE, Young Investigator Award - 2003
Prostate Cancer Foundation Award - 2004
Prostate Cancer Foundation Award - 2005
Damon Runyon Cancer Research Foundation Clinical Investigator Award - 2005
Department of Defense, New Investigator Award - 2006
Department of Defense, Physician Research Training Award - 2006
Department of Defense, Idea Development Award - 2009
Elected to American Society of Clinical Investigation
Selected Publications
- Klink JC, Tewari AK, Masko EM, Antonelli J, Febbo PG, Cohen P, Dewhirst MW, Pizzo SV, Freedland SJ. Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. Prostate. 2013 May; 73(7):754-62.
View on PubMed - Kelley RK, Atreya C, Venook AP, Febbo PG. Predictive biomarkers in advance of a companion drug: ahead of their time? J Natl Compr Canc Netw. 2012 Mar; 10(3):303-9.
View on PubMed - Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H, Korshunov A, Read TA, Sun JL, Schmitt EM, Miller CR, Buckley AF, McLendon RE, Westbrook TF, Northcott PA, Taylor MD, Pfister SM, Febbo PG, Wechsler-Reya RJ. An animal model of MYC-driven medulloblastoma. Cancer Cell. 2012 Feb 14; 21(2):155-67.
View on PubMed - Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer. 2012 Oct 1; 118(19):4777-84.
View on PubMed - Engstrom PF, Bloom MG, Demetri GD, Febbo PG, Goeckeler W, Ladanyi M, Loy B, Murphy K, Nerenberg M, Papagni P, Robson M, Sweetman RW, Tunis S, Demartino J, Larsen JK. NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement. J Natl Compr Canc Netw. 2011 Dec; 9 Suppl 6:S1-16.
View on PubMed - Stewart SB, Bañez LL, Robertson CN, Freedland SJ, Polascik TJ, Xie D, Koontz BF, Vujaskovic Z, Lee WR, Armstrong AJ, Febbo PG, George DJ, Moul JW. Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. J Urol. 2012 Jan; 187(1):103-8.
View on PubMed - Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw. 2011 Nov; 9 Suppl 5:S1-32; quiz S33.
View on PubMed - Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR. Retraction: Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2011 Jan; 17(1):135.
View on PubMed - Hsu DS, Kim MK, Balakumaran BS, Acharya CR, Anders CK, Clay T, Lyerly HK, Drake CG, Morse MA, Febbo PG. Immune signatures predict prognosis in localized cancer. Cancer Invest. 2010 Aug; 28(7):765-73.
View on PubMed - Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, George DJ, Gurganus R, De Marzo AM, Carducci MA. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res. 2010 Jun 1; 16(11):3057-66.
View on PubMed - Balakumaran BS, Herbert JT, Febbo PG. MYC activity mitigates response to rapamycin in prostate cancer through 4EBP1-mediated inhibition of autophagy. Autophagy. 2010 Feb; 6(2):281-2.
View on PubMed - Foye A, Febbo PG. Cancer gene profiling in prostate cancer. Methods Mol Biol. 2010; 576:293-326.
View on PubMed - Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, Leung JY, Sullivan BA, Hahn WC, Loda M, Febbo PG. MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res. 2009 Oct 1; 69(19):7803-10.
View on PubMed - Armstrong AJ, Febbo PG. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Oncologist. 2009 Aug; 14(8):816-27.
View on PubMed - Febbo PG. Genomic approaches to outcome prediction in prostate cancer. Cancer. 2009 Jul 1; 115(13 Suppl):3046-57.
View on PubMed - Febbo PG. Epigenetic events highlight the challenge of validating prognostic biomarkers during the clinical and biologic evolution of prostate cancer. J Clin Oncol. 2009 Jul 1; 27(19):3088-90.
View on PubMed - Mavropoulos JC, Buschemeyer WC, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, Pizzo SV, Freedland SJ. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev Res (Phila). 2009 Jun; 2(6):557-65.
View on PubMed - Chang JT, Carvalho C, Mori S, Bild AH, Gatza ML, Wang Q, Lucas JE, Potti A, Febbo PG, West M, Nevins JR. A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell. 2009 Apr 10; 34(1):104-14.
View on PubMed - Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009 Apr 1; 101(7):519-32.
View on PubMed - Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS, Febbo PG. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol. 2009 Apr 20; 27(12):2022-9.
View on PubMed
View on UCSF Profiles
